Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

20. Dezember 2013 16:15 ET | Quelle: Zogenix

Zogenix Reports Granting of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, Dec. 20, 2013 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system disorders and...
17. Dezember 2013 08:30 ET | Quelle: Zogenix

Zogenix Appoints Chief Medical Officer and Expands Medical Leadership Team

SAN DIEGO, Dec. 17, 2013 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system disorders and...
11. Dezember 2013 07:30 ET | Quelle: Zogenix

Zogenix Reports Granting of Inducement Awards

SAN DIEGO, Dec. 11, 2013 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system disorders and...
10. Dezember 2013 08:30 ET | Quelle: Zogenix

Zogenix Announces FDA Approval of 4 mg SUMAVEL(R) DosePro(R) (sumatriptan injection) Needle-Free Delivery System

SAN DIEGO, Dec. 10, 2013 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system (CNS) disorders...
04. Dezember 2013 07:30 ET | Quelle: Zogenix

Zogenix to Present at the Oppenheimer 24th Annual Healthcare Conference

SAN DIEGO, Dec. 4, 2013 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system...
03. Dezember 2013 07:30 ET | Quelle: Zogenix

Zogenix and Battelle Expand DosePro Technology Business Agreement

SAN DIEGO and COLUMBUS, Ohio, Dec. 3, 2013 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX) and Battelle today announced that they have entered into a new long-term collaborative agreement regarding...
12. November 2013 16:30 ET | Quelle: Zogenix

Zogenix Announces Closing of Public Offering of Common Stock, Including Full Exercise of Over-Allotment Option by Underwriters

SAN DIEGO, Nov. 12, 2013 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system disorders and...
05. November 2013 19:50 ET | Quelle: Zogenix

Zogenix Prices Public Offering of Common Stock

SAN DIEGO, Nov. 5, 2013 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system disorders and...
04. November 2013 06:51 ET | Quelle: Zogenix

Zogenix Announces Proposed Public Offering of Common Stock

SAN DIEGO, Nov. 4, 2013 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system disorders and...
04. November 2013 06:00 ET | Quelle: Zogenix

Zogenix Reports Third Quarter 2013 Financial Results

Business Highlights and Milestones Received FDA Approval for Zohydro™ ER (hydrocodone bitartrate), an extended-release oral formulation of hydrocodone without acetaminophen Announced...

Vorherige Seite

Nächste Seite